Wudhikarn, Kitsada http://orcid.org/0000-0001-9528-8681
Palomba, M. Lia http://orcid.org/0000-0001-5099-9156
Pennisi, Martina
Garcia-Recio, Marta
Flynn, Jessica R.
Devlin, Sean M.
Afuye, Aishat http://orcid.org/0000-0002-5751-3283
Silverberg, Mari Lynne
Maloy, Molly A.
Shah, Gunjan L.
Scordo, Michael
Dahi, Parastoo B. http://orcid.org/0000-0002-0794-3226
Sauter, Craig S.
Batlevi, Connie L. http://orcid.org/0000-0002-9036-9463
Santomasso, Bianca D.
Mead, Elena
Seo, Susan K.
Perales, Miguel-Angel http://orcid.org/0000-0002-5910-4571
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 4 May 2020
Revised: 29 June 2020
Accepted: 21 July 2020
First Online: 5 August 2020
Conflict of interest
: K.W., M.P., J.R.F., S.M.D., A.A., M.L.S., M.A.M., and S.K.S. have no relevant conflict of interest. M.G.R. reports receiving honoraria from Takeda and Janssen Pharmaceutical. M.S. has served as a paid consultant for McKinsey & Company, Angiocrine Bioscience, Inc., and Omeros Corporation. He has received research funding from Angiocrine Bioscience, Inc. He has served on an ad hoc advisory board for Kite—A Gilead Company. G.L.S. receives research funding from Amgen and Janssen Pharmaceutical. C.L.B. serves as a paid consultant for Life Sci, GLG, Juno/Celgene, Seattle Genetics and Kite/Gilead. She reports receiving research funding from Janssen Pharmaceutical, Novartis, Epizyme, Xynomics and Bayer. She receives honorarium from Dava Oncology. M.L.P. has served on ad hoc advisory board for Kite and Novartis. P.B.D. serves on the advisory board for Kite/Gilead. C.S.S. has served as a paid consultant on advisory boards for Juno Therapeutics, Sanofi-Genzyme, Spectrum Pharmaceuticals, Novartis, Genmab, Precision Biosciences, Kite, a Gilead Company, Celgene, Gamida Cell and GSK. He has received research funds for clinical trials from Juno Therapeutics, Celgene, Precision Biosciences and Sanofi-Genzyme. B.D.S. provides consultancy for Kite/Gilead, Juno/Celgene and Janssen. She also receives research support from ADC Therapeutics. M.A.P. reports honoraria from Kite/Gilead, Abbvie, Bellicum, Bristol-Myers Squibb, Incyte, Merck, Novartis, Nektar Therapeutics, Omeros, and Takeda. He serves on DSMBs for Servier and Medigene, and the scientific advisory boards of MolMed and NexImmune. He has received research support for clinical trials from Incyte, Kite/Gilead and Miltenyi Biotec. He serves in a volunteer capacity as a member of the Board of Directors of the American Society for Transplantation and Cellular Therapy (ASTCT) and Be the Match (National Marrow Donor Program, NMDP), as well as on the CIBMTR Cellular Immunotherapy Data Resource (CIDR) Committee.